Kepler Uniklinikum Harnesses SOPHiA GENETICS' Tech for Blood Cancer Diagnostics
Portfolio Pulse from Benzinga Newsdesk
SOPHiA GENETICS (NASDAQ:SOPH) has announced that Kepler Uniklinikum, Austria's second largest hospital, is now using its SOPHiA DDM™ Platform for next-generation sequencing (NGS) testing and diagnostics of blood-related cancers. This implementation aims to enhance the hospital's in-house NGS testing capabilities and expand its offerings to patients with blood cancers and disorders.
June 13, 2024 | 10:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SOPHiA GENETICS has partnered with Kepler Uniklinikum to implement its SOPHiA DDM™ Platform for advanced blood cancer diagnostics, potentially increasing the platform's adoption and revenue.
The partnership with a major hospital like Kepler Uniklinikum can significantly boost the adoption of SOPHiA GENETICS' platform, potentially leading to increased revenue and market presence. The focus on blood cancer diagnostics, a critical area in healthcare, further underscores the importance of this development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100